Skip to content
HomeLatest newsJohnson & Johnson moves up eight spots on the Gartner Top 25 Supply Chain Index
A photo of a scientist in a lab

Johnson & Johnson moves up eight spots on the Gartner Top 25 Supply Chain Index

The company’s supply chain division is honored by a leading research and advisory firm for setting the standard in healthcare, and transforming customer experience.

Johnson & Johnson’s supply chain marked another step on its journey to build the best supply chain in the world: It scored its highest-ever ranking on the most widely-recognized list of top performers.
On May 25, Gartner announced its annual Top 25 Supply Chain Index. Johnson & Johnson ranked #13, moving up eight spots from its 2016 ranking. Not only was this the biggest leap forward of any company on the list, but Johnson & Johnson is now the only healthcare supply chain included on this prominent cross-industry ranking of large cap company supply chains.

Top 25 Supply Chain Announcement

This year’s Gartner rankings

Gartner, a leading research and advisory firm in the supply chain and information technology space, noted Johnson & Johnson’s steady improvement in delivering high-quality metrics, customer satisfaction and cost efficiencies.

The selection committee also called attention to the way Johnson & Johnson’s supply chain has leveraged technology to drive innovation, while continuing to enhance its environmental sustainability and corporate social responsibility.

“This latest ranking is a strong testament to the great work done by all of our supply chain associates around the world every day to meet the needs of the customers, patients and consumers we are privileged to serve,” says Kathy Wengel, Chief Supply Chain Officer for Johnson & Johnson. “It’s exciting and very motivating for all of us at Johnson & Johnson to be ranked so highly among companies that are known for supply chain excellence. We will keep pushing ourselves to continually set the new standard in healthcare as we transform the customer experience and advance our operational capabilities to strengthen our competitive edge.”

More from Johnson & Johnson

This scientist couldn’t save his father from lung cancer—but the targeted treatments Robert Zhao, Ph.D., has since developed have helped countless others

Learn more about Zhao, his partnership with Johnson & Johnson and antibody-drug conjugates—a new type of cancer therapy that targets and kills cancer cells without harming healthy cells.

After their husbands were diagnosed with multiple myeloma, these 3 care partners became health equity activists

Kimberly Alexander, Michelle Ware-Ivy and Marsha Calloway-Campbell learned firsthand that Black individuals develop multiple myeloma at higher rates. That’s why they joined Johnson & Johnson’s That’s My Word® health equity campaign, which builds awareness about the disparities surrounding this rare blood cancer.

How Johnson & Johnson is working to get medications to people around the world who need them most

In the just-released 2024 Access to Medicine Index, the company ranks among the top 5 improving access to medicines.